Diede van Ens

Diede van Ens

Auto-generated profile, based on publicly available information

Diede van Ens

Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2022 in The European Physical Journal E
Verified
Journal Article
Open access
PDF file
LBLianne Beunk
Lianne Beunk
GBGert-Jan Bakker
Gert-Jan Bakker
DEDiede van Ens
Diede van Ens
JBJeroen Bugter
Jeroen Bugter
FGFloris Gal
Floris Gal
Katarina WolfKatarina Wolf
Katarina Wolf
The interstitial tumor microenvironment is composed of heterogeneously organized collagen-rich porous networks as well as channel-like structures and interfaces which provide both barriers and guidance for invading cells. Tumor cells invading 3D random porous collagen networks depend upon actomyosin contractility to deform and translocate the nucleus, whereas Rho/Rho-associated kinase-dependent contractility is largely dispensable for migration in stiff capillary-like confining microtracks. To investigate whether this dichotomy of actomyosin contractility dependence also applies to physiological, deformable linear collagen environments, we developed nearly barrier-free collagen-scaffold microtracks of varying cross section using two-photon laser ablation. Both very narrow and wide tracks supported single-cell migration by either outward pushing of collagen up to four times when tracks were narrow, or cell pulling on collagen walls down to 50% of the original diameter by traction forces of up to 40 nN when tracks were wide, resulting in track widths optimized to single-cell diameter. Targeting actomyosin contractility by synthetic inhibitors increased cell elongation and nuclear shape change in narrow tracks and abolished cell-mediated deformation of both wide and narrow tracks. Accordingly, migration speeds in all channel widths reduced, with migration rates of around 45-65% of the original speed persisting. Together, the data suggest that cells engage actomyosin contraction to reciprocally adjust both own morphology and linear track width to optimal size for effective cellular locomotion. Graphic

1 April 2021 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
JSJesper van Eck van der Sluijs
Jesper van Eck van der Sluijs
DEDiede van Ens
Diede van Ens
STSoley Thordardottir
Soley Thordardottir
DVDenise Vodegel
Denise Vodegel
IHInge Hermens
Inge Hermens
WHWillemijn Hobo
Willemijn Hobo
Allogeneic stem cell transplantation (alloSCT), following induction chemotherapy, can be curative for hemato-oncology patients due to powerful graft-versus-tumor immunity. However, disease recurrence remains the major cause of treatment failure, emphasizing the need for potent adjuvant immunotherapy. In this regard, dendritic cell (DC) vaccination is highly attractive, as DCs are the key orchestrators of innate and adaptive immunity. Natural DC subsets are postulated to be more powerful compared with monocyte-derived DCs, due to their unique functional properties and cross-talk capacity. Yet, obtaining sufficient numbers of natural DCs, particularly type 1 conventional DCs (cDC1s), is challenging due to low frequencies in human blood. We developed a clinically applicable culture protocol using donor-derived G-CSF mobilized CD34+ hematopoietic progenitor cells (HPCs) for simultaneous generation of high numbers of cDC1s, cDC2s and plasmacytoid DCs (pDCs). Transcriptomic analyses demonstrated that these ex vivo-generated DCs highly resemble their in vivo blood counterparts. In more detail, we demonstrated that the CD141+CLEG9A+ cDC1 subset exhibited key features of in vivo cDC1s, reflected by high expression of co-stimulatory molecules and release of IL-12p70 and TNF-α. Furthermore, cDC1s efficiently primed alloreactive T cells, potently cross-presented long-peptides and boosted expansion of minor histocompatibility antigen-experienced T cells. Moreover, they strongly enhanced NK cell activation, degranulation and anti-leukemic reactivity. Together, we developed a robust culture protocol to generate highly functional blood DC subsets for in vivo application as tailored adjuvant immunotherapy to boost innate and adaptive anti-tumor immunity in alloSCT patients.

11 June 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
DEDiede van Ens
Diede van Ens
CMCharlotte M. Mousset
Charlotte M. Mousset
THTim J. A. Hutten
Tim J. A. Hutten
AWAnniek B. van der Waart
Anniek B. van der Waart
DCDiana Campillo-Davo
Diana Campillo-Davo
WHWillemijn Hobo
Willemijn Hobo

20 September 2023 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
JSJesper van Eck van der Sluijs
Jesper van Eck van der Sluijs
DEDiede van Ens
Diede van Ens
JBJolanda Brummelman
Jolanda Brummelman
DHDaan Heister
Daan Heister
ASAastha Sareen
Aastha Sareen
WHWillemijn Hobo
Willemijn Hobo
Allogeneic stem cell transplantation (alloSCT) can be curative for hemato-oncology patients due to effective graft-versus-tumor immunity. However, relapse remains the major cause of treatment failure, emphasizing the need for adjuvant immunotherapies. In this regard, post-transplantation dendritic cell (DC) vaccination is a highly interesting strategy to boost graft-versus-tumor responses. Previously, we developed a clinically applicable protocol for simultaneous large-scale generation of end-stage blood DC subsets from donor-derived CD34+ stem cells, including conventional type 1 and 2 DCs (cDC1s and cDC2s), and plasmacytoid DCs (pDCs). In addition, the total cultured end-product (DC-complete vaccine), also contains non-end-stage-DCs (i.e. non-DCs). In this study, we aimed to dissect the phenotypic identity of these non-DCs and their potential immune modulatory functions on the potency of cDCs and pDCs in stimulating tumor-reactive CD8+ T and NK cell responses, in order to obtain rationale for clinical translation of our DC-complete vaccine. The non-DC compartment was heterogeneous and comprised of myeloid progenitors and (immature) granulocyte- and monocyte-like cells. Importantly, non-DCs potentiated toll-like receptor-induced DC maturation, as reflected by increased expression of co-stimulatory molecules and enhanced cDC-derived IL-12 and pDC-derived IFN-α production. Additionally, antigen-specific CD8+ T cells effectively expanded upon DC-complete vaccination in vitro and in vivo. This effect was strongly augmented by non-DCs in an antigen-independent manner. Moreover, non-DCs did not impair in vitro DC-mediated NK cell activation, degranulation nor cytotoxicity. Notably, in vivo i.p. DC-complete vaccination activated i.v. injected NK cells. Together, these data demonstrate that the non-DC compartment potentiates DC-mediated activation and expansion of antigen-specific CD8+ T cells and do not impair NK cell responses in vitro and in vivo. This underscores the rationale for further clinical translation of our CD34+-derived DC-complete vaccine in hemato-oncology patients post alloSCT.

21 May 2021 in Journal of Innate Immunity
Verified
Journal Article
Open access
PDF file
GLGregory R. Lum
Gregory R. Lum
VMVicki Mercado
Vicki Mercado
DEDiede van Ens
Diede van Ens
VNVictor Nizet
Victor Nizet
JKJacqueline M. Kimmey
Jacqueline M. Kimmey
KPKathryn Patras
Kathryn Patras
Group B Streptococcus (GBS) is a leading cause of neonatal morbidity and mortality, and the primary source of exposure is the maternal vagina. Intrapartum antibiotic prophylaxis for GBS-positive mothers has reduced the incidence of GBS early-onset disease, however, potential long-lasting influence of an antibiotic-altered neonatal microbiota, and the frequent clinical sequelae in survivors of invasive GBS infection, compels alternative treatment options for GBS. Here, we examined the role of transcription factor hypoxia-inducible factor 1 alpha (HIF-1α), widely recognized as a regulator of immune activation during infection, in the host response to GBS. Given the importance of endogenous HIF-1α for innate immune defense, and the potential utility of HIF-1α stabilization in promoting bacterial clearance, we hypothesized that HIF-1α could play an important role in coordinating host responses to GBS in colonization and systemic disease. Counter to our hypothesis, we found that GBS infection did not induce HIF-1α expression in vaginal epithelial cells or murine macrophages, nor did HIF-1α deficiency alter GBS colonization or pathogenesis in vivo. Furthermore, pharmacological enhancement of HIF-1α did not improve control of GBS in pathogenesis and colonization models, while displaying inhibitory effects in vaginal epithelial cytokines and immune cell killing in vitro. Taken together, we conclude that HIF-1α is not a prominent aspect of the host response to GBS colonization or invasive disease, and its pharmacological modulation is unlikely to provide significant benefit against this important neonatal pathogen.

29 November 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JSJesper van Eck van der Sluijs
Jesper van Eck van der Sluijs
DEDiede van Ens
Diede van Ens
AGAyla Grotens
Ayla Grotens
EMEsther Fernández Merino
Esther Fernández Merino
NDNadia Dubois
Nadia Dubois
WHWillemijn Hobo
Willemijn Hobo
Allogeneic stem cell transplantation (alloSCT) can be curative for acute myeloid leukemia (AML) patients due to graft-versus-tumor immune responses. However, relapse post-alloSCT remains a major clinical challenge, underscoring the necessity for adjuvant treatments that both reduce tumor load before alloSCT and strengthen natural killer (NK) and T cell immunity posttransplant. The hypomethylating agent decitabine (DAC) holds promise as it is well-tolerated and has direct anti-proliferative and pro-apoptotic effects on leukemic cells. In addition, DAC modulates tumor immunogenicity and exhibits immunomodulatory properties. Yet, integral insight into the impact of DAC addition to the pre-alloSCT conditioning on the immunophenotype and function of NK and T cells post-alloSCT is lacking. Here, we investigated the immunomodulatory effects of adding DAC to the pre-alloSCT conditioning on the NK and T cell landscape and function in AML patients post-transplantation. This retrospective cohort study included AML patients who received alloSCT with (n=30) or without (n=22) DAC as part of the condition regimen. Peripheral blood samples were collected three and six months post-alloSCT. High dimensional flow cytometry was used to assess the phenotypic profiles, whereas proliferation, cytokine production and cytotoxicity assays were performed to study their function. Irrespective of the conditioning regimen, checkpoint molecules on NK cells, including PD-1, TIM-3, LIGHT and OX40 were low post-alloSCT. Notably, DAC conditioning significantly increased the abundance of mature NK cell clusters co-expressing KIRah, KIRb, CD69, CD57 and DNAM-1. Interestingly, NK cells from DAC conditioned patients retained their cytotoxic and cytokine production capacity, with mature NK cells demonstrating significantly enhanced responsiveness to K562 stimulation compared to immature NK cells. Within the CD4+ T cells, DAC conditioning reduced the frequencies of TH1/TH17 cells and a proportion of TH17 cells. Interestingly, DAC treatment led to a diminished abundance of CD8+ T cell clusters co-expressing immune checkpoint molecules, including PD-1, TIGIT, KLRG1, TIM-3 and CD57, implying a less terminally differentiated phenotype. Functionally, CD4+ and CD8+ T cells from DAC conditioned patients demonstrated robust proliferation in response to anti-CD3 stimulation and exhibited polyfunctionality, producing IFN-γ, TNF-α and IL-2. Notably, the higher abundance of CD8⁺ T cells co-expressing inhibitory checkpoint molecules in non-DAC-conditioned patients was inversely associated with IL-2 production upon polyclonal stimulation. Overall, addition of DAC to the conditioning regimen was associated with favorable immunomodulatory effects on NK and T cells post-alloSCT in AML patients. These findings suggest that DAC may enhance donor NK and T cell-mediated graft-versus-tumor responses supporting its further clinical evaluation as an adjuvant prior to alloSCT.